Free Trial

Prime Medicine Q1 2024 Earnings Report

Prime Medicine logo
$1.78 -0.21 (-10.30%)
As of 04:00 PM Eastern

Prime Medicine EPS Results

Actual EPS
-$0.44
Consensus EPS
-$0.45
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Prime Medicine Revenue Results

Actual Revenue
$0.59 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Prime Medicine Announcement Details

Quarter
Q1 2024
Time
N/A
Remove Ads

Prime Medicine Earnings Headlines

Prime Medicine (NYSE:PRME) Price Target Raised to $16.00
Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
Wedbush Estimates Prime Medicine FY2029 Earnings
Prime Medicine price target raised to $16 from $15 at Chardan
See More Prime Medicine Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Prime Medicine? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Prime Medicine and other key companies, straight to your email.

About Prime Medicine

Prime Medicine (NYSE:PRME), a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.

View Prime Medicine Profile

More Earnings Resources from MarketBeat